Iterum Therapeutics plc (ITRM)

On March 27, 2026, an order was made by the High Court in Ireland appointing Damien Murran and Jennifer McMahon, each of Teneo Restructuring (Ireland) Limited, as Joint Liquidators to both Iterum Therapeutics plc and Iterum Therapeutics International Limited. Stakeholders with questions should send any inquiries to the office of the liquidators at Iterum.Liquidation@teneo.com.

Notification to Shareholders (10 July 2026)

As per the Companies Act 2014, share transfers after the date of the Joint Liquidators appointment on 27 March 2026, are not permitted without the prior written consent of the Joint Liquidators. Accordingly, from 27 March 2026, no shares in Iterum Therapeutics Public Limited Company (in Liquidation) can be validly transferred.

Our Challenge

Antibiotic Resistant Infections

Every year, at least two million Americans are infected with bacteria that resist antibiotics. At least 23,000 people die as a direct result. Multi-drug resistant pathogens are a global crisis. Physicians and patients urgently need new options.

Learn More

Our Promise

New Effective Oral Treatments

Responding to specific medical need, Iterum is developing sulopenem - the first oral and IV penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative infections in both the hospital and community settings

Learn More

Tackling serious challenges, delivering unique solutions

About Us

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens.

Our Company

Careers

Our culture is defined by collaboration and a shared motivation to leverage the power of ingenuity to develop new solutions that address the ever-increasing global threat of resistant bacterial infections.